Companies / Amylyx Pharmaceuticals, Inc. / Activity
Activity — Amylyx Pharmaceuticals, Inc.
22 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | Cohen Joshua B CEO | Grant | Common Stock | $0 | +249K +7.46% | 3,583,548 3.22% of shares | low |
| Mar 5, 2026 | Klee Justin B. CEO | Grant | Common Stock | $0 | +249K +7.46% | 3,583,481 3.22% of shares | low |
| Jan 16, 2026 | Cohen Joshua B CEO | Exercise | Common Stock | $21.3K | +3K +0.08% | 3,381,439 3.03% of shares | low |
| Jan 16, 2026 | Klee Justin B. CEO | Exercise | Common Stock | $21.6K | +3K +0.08% | 3,381,393 3.03% of shares | low |
| Jan 16, 2026 | Cohen Joshua B CEO | Sell | Common Stock | $27.3K | -2K -0.06% | 3,379,465 3.03% of shares | low |
| Jan 16, 2026 | Klee Justin B. CEO | Sell | Common Stock | $27.7K | -2K -0.06% | 3,379,398 3.03% of shares | low |
| Jan 6, 2026 | Klee Justin B. CEO | Sell | Common Stock | $85.6K | -8K -0.23% | 3,317,586 2.98% of shares | low |
| Jan 6, 2026 | Cohen Joshua B CEO | Sell | Common Stock | $85.6K | -8K -0.23% | 3,317,632 2.98% of shares | low |
| Feb 2, 2026 | Cohen Joshua B CEO | Sell | Common Stock | $227.6K | -16K -0.46% | 3,363,965 3.02% of shares | medium |
| Feb 2, 2026 | Klee Justin B. CEO | Sell | Common Stock | $227.6K | -16K -0.46% | 3,363,898 3.02% of shares | medium |
| Mar 2, 2026 | Klee Justin B. CEO | Sell | Common Stock | $423.8K | -29K -0.87% | 3,334,616 2.99% of shares | medium |
| Mar 2, 2026 | Cohen Joshua B CEO | Sell | Common Stock | $424.1K | -29K -0.87% | 3,334,683 2.99% of shares | medium |
| Jan 15, 2026 | Klee Justin B. CEO | Exercise | Common Stock | $1.49M | +197K +5.94% | 3,514,739 3.15% of shares | low |
| Jan 15, 2026 | Cohen Joshua B CEO | Exercise | Common Stock | $1.49M | +197K +5.94% | 3,514,814 3.15% of shares | low |
| Jan 15, 2026 | Klee Justin B. CEO | Sell | Common Stock | $1.85M | -136K -3.87% | 3,378,546 3.03% of shares | medium |
| Jan 15, 2026 | Cohen Joshua B CEO | Sell | Common Stock | $1.85M | -136K -3.87% | 3,378,621 3.03% of shares | medium |
| Mar 5, 2026 | Cohen Joshua B CEO | Grant | Stock Option (Right to Buy) | — | +373K | 373,295 0.34% of shares | low |
| Mar 5, 2026 | Klee Justin B. CEO | Grant | Stock Option (Right to Buy) | — | +373K | 373,295 0.34% of shares | low |
| Jan 16, 2026 | Cohen Joshua B CEO | Exercise | Stock Option (Right to Buy) | — | -3K -100.00% | 0 0.00% of shares | low |
| Jan 15, 2026 | Cohen Joshua B CEO | Exercise | Stock Option (Right to Buy) | — | -197K -98.59% | 2,818 <0.01% of shares | low |
| Jan 16, 2026 | Klee Justin B. CEO | Exercise | Stock Option (Right to Buy) | — | -3K -100.00% | 0 0.00% of shares | low |
| Jan 15, 2026 | Klee Justin B. CEO | Exercise | Stock Option (Right to Buy) | — | -197K -98.58% | 2,847 <0.01% of shares | low |